The National Center for Toxicological Research of the US Food and Drug Administration (FDA) hosted a workshop to discuss current gaps and challenges in translating preclinical cardiovascular safety data to humans. This white paper summarizes the topics presented by speakers from academia, industry, and government intended to address the theme of improving cardiotoxicity assessment in drug development.

PUBLICATION: Circulation Research (2019)

AUTHORS: Li Pang, Philip Sager, Xi Yang, Hong Shi, Frederick Sannajust, Mathew Brock, Joseph C. Wu, Najah Abi-Gerges, Beverly Lyn-Cook, Brian R. Berridge, Norman Stockbridge